DEVI PHARMATECH

Promoted jointly by an Internationally Acclaimed Business House and Pharma Professionals with Rich Pedigree and Proven Entrepreneurial Capability

 

VISION

To Emerge as a Reliable & Trustworthy Partner for the Manufacture & Supply of Active Substances & Key Intermediates to Global Healthcare Industry

Roadmap

 

 

 

MARCH ’23

  • Fully Functional R&D
  • Kilo Lab, Pilot Plant
  • 140KL Manufacturing Facility
  • 3 Clean Rooms
  • 7 Products ready for Tech Transfer
   

 

 

BY MARCH’24

  • 10 Additional products
  • Local GMP & WHO GMP accreditation
  • GDUFA Paid
  • 3 New US DMF & CEP to be filed
  • Manufacturing capacity enhanced to 250Kl

 

BY MARCH’25

  • Product portfolio-25 products
  • EU-GMP Accreditation
  • 5 New USDMF & CEP to be filed
  • Manufacturing Capacity Enhanced to 350 KL
  • Additional 2 Clean Rooms(T-5)

BY MARCH’27

  • Product portfolio-30 products
  • 10 New US DMF and CEP to be filed
  • Manufacturing capacity enhanced to 500kl
  • Additional 4 Clean Rooms(T-9)

Capabilities

RESEARCH & DEVELOPMENT
(GLP COMPLIANT)

5000SFT State of the Art R&D Facility @ Hyderabad
Capable of Developing 10 products per Year

Operational by Nov‘2022

20+ members scientific team headed by a scientist with over 30+ years of experience
Capability to perform high-temperature, Cryogenic, HVD, and Hydrogenation reactions
In-house screening for Nitrosamines and Genotoxic Impurities for which instruments like LC/MS and GC/MS will be added by FY 24
Patent Landscaping to facilitate the early launch

MANUFACTURING
(cGMP COMPLIANT)

Kilo Lab

Pilot Plant

All glass assembly to handle sub-kilo products

Process equipment ranging from 63L to 6300L in both SSR and GLR
Dedicated blocks to carry out high-temperature, Cryogenic, HVD, and Hydrogenation reactions
Phase 1-100KL Manufacturing Block, 40KL for Hazardous Chemistry,
3 Clean Rooms

Product Strategy

Our Approach

  • Single process for all markets
  • Multimarket potential
  • Seamless support across the value chain
  • Scalable and cost-competitive
  • Clean Regulatory Pathway

Life Cycle Management

End to End Support From Development to Post Commercialization.

Product List

iiBy March 23’
  • Gliclazide
  • Ketorolac
  • Montelukast
  • Etoricoxib
  • Glimepiride
  • Benfotiamine
  • Terbinafine

By March 24’

  • Lercanidipine
  • Pyridostigmine
  • Cromolyn Sodium
  • Bezafibrate
  • Ciprofibrate
  • Epalrestat
  • Ezetimibe
  • Acipimox
  • Pentoxifylline
  • Tizanidine
  • Terizidone
  • Ebastine

Product Strategy

OUR APPROACH

  • Single process for all markets
  • Multimarket potential
  • Seamless support across the value chain
  • Scalable and cost-competitive
  • Clean Regulatory Pathway

PRODUCT LIST

By March 23’
  • Gliclazide
  • Ketorolac
  • Montelukast
  • Etoricoxib
  • Glimepiride
  • Benfotiamine
  • Terbinafine

    LIFE CYCLE MANAGEMENT

    End to End Support From Development to Post Commercialization.

    PRODUCT LIST

    TERIZIDONEBy March 24’

    • Lercanidipine
    • Pyridostigmine
    • Cromolyn Sodium
    • Bezafibrate
    • Ciprofibrate
    • Epalrestat
    • Ezetimibe
    • Acipimox
    • Pentoxifylline
    • Tizanidine
    • Terizidone
    • Ebastine

    Strengths

    Leadership

    Team with Pedigree

    Support

    Proactive Support in Product Lifecycle Management

    Strong Financials

    Sound financials for upfront investment to leverage potential opportunities

    Project Management

    Proven Capability

    Commitment to Quality

    Highest Commitment to Quality Systems & Practices

    ENVIRONMENTAL SUSTAINABILITY

    Strict Adherence to Environmental Sustainability

    Customer Engagement

    IN-HOUSE DEVELOPMENT & SUPPLY

    SELF OR COFUNDED DEVELOPMENT

    • CDMO OPPORTUNITIES
    • COLLABORATIVE APPROACH FOR NICHE/TERRITORY SPECIFIC PRODUCTS

    FEE FOR SERVICE

    • END TO END DEVELOPMENT
    • MANUFACTURING

    Competent in-house team of medical professionals, scientists & litigation experts to facilitate if required patent landscaping, novel route identification, design of clinical studies etc.

    Can extend formulation development support through associate companies

    Leadership Team

    R Sirish Kumar

    CEO

    BITS Pilani – B. Tech Chem Engg & M. Sc. Chemistry. SIMSREE, University of Mumbai – MMS. 30+ Years of Professional & Entrepreneurial Experience in APIs & Formulation

    Y Ravi Kumar

    COO

    30+ Years of Professional & Entrepreneurial Experience in APIs & Formulations

    Dr Y Samarendra

    Director – Strategy & Business Development

    Dr Y Veerendra

    Director – Operations

    Dr R Butchi Reddy

    Director – Technical

    PhD, PG Diploma in IPR
    30+ Years of experience in R&D and Tech Operations

    Contact Us

    info@devipharmatech.com
    +91-891-2595672, 2595673

    Regd. Office

    D.No.6-21-7,East Point Colony, Visakhapatnam-530017

     

    Site Address

    Plot No. 12 & 15, Phase III
    APIIC-Industrial Park, Parawada, Visakhapatnam-531019, India

    R&D

    3rd Floor, Unit D 4-7, Industrial Estate, Moula Ali Hyderabad – 500 040